Literature DB >> 17884394

Evaluation of the immune response following a short oral vaccination schedule with hepatitis B antigen encapsulated into alginate-coated chitosan nanoparticles.

Olga Borges1, Joana Tavares, Adriano de Sousa, Gerrit Borchard, Hans E Junginger, Anabela Cordeiro-da-Silva.   

Abstract

The purpose of this work was to assess the ability of recombinant hepatitis B vaccine, encapsulated in alginate-coated chitosan nanoparticles, to induce local and systemic immune responses following oral vaccination. The antigen was administered either alone or in combination with the immunopotentiator, synthetic oligodeoxynucleotide containing immunostimulatory CpG motif (CpG ODN) as adjuvant, and associated or not with the alginate-coated chitosan nanoparticles. After two immunizations the group I (HBsAg associated with nanoparticles) and the group VI (HBsAg and CpG, both associated with nanoparticles) showed enhanced immune responses. Both groups showed significant higher values of the CD69 expression in CD4+ and CD8+ T-lymphocytes and lower values of this marker in B lymphocytes. Moreover, a strongest proliferative response of the splenocytes, ex vivo stimulated with concanavalin A, was observed in the same groups. Although with a presence of non-responder mice within the groups, only mice of the groups I and VI elicited the generation of anti-HBsAg antibodies detected in serum (IgG) and in the intestinal washings (sIgA). The results demonstrated that coated chitosan nanoparticles might have potential for being used as a deliver system for oral vaccination with the recombinant hepatitis B surface antigen.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17884394     DOI: 10.1016/j.ejps.2007.08.005

Source DB:  PubMed          Journal:  Eur J Pharm Sci        ISSN: 0928-0987            Impact factor:   4.384


  21 in total

Review 1.  Engineered nanoparticulate drug delivery systems: the next frontier for oral administration?

Authors:  Roudayna Diab; Chiraz Jaafar-Maalej; Hatem Fessi; Philippe Maincent
Journal:  AAPS J       Date:  2012-07-06       Impact factor: 4.009

2.  Novel antigen delivery technologies: a review.

Authors:  Deepika Jain; Vikas Jain; Ranjit Singh
Journal:  Drug Deliv Transl Res       Date:  2011-04       Impact factor: 4.617

Review 3.  Progress towards a needle-free hepatitis B vaccine.

Authors:  Filipa Lebre; Gerrit Borchard; Maria Conceição Pedroso de Lima; Olga Borges
Journal:  Pharm Res       Date:  2010-11-19       Impact factor: 4.200

4.  Novel approaches to oral immunization for hepatitis B.

Authors:  Shailja Tiwari; Suresh P Vyas
Journal:  Curr Infect Dis Rep       Date:  2011-02       Impact factor: 3.725

Review 5.  Current state and challenges in developing oral vaccines.

Authors:  Julia E Vela Ramirez; Lindsey A Sharpe; Nicholas A Peppas
Journal:  Adv Drug Deliv Rev       Date:  2017-04-22       Impact factor: 15.470

6.  Oral Biologic Delivery: Advances Toward Oral Subunit, DNA, and mRNA Vaccines and the Potential for Mass Vaccination During Pandemics.

Authors:  Jacob William Coffey; Gaurav Das Gaiha; Giovanni Traverso
Journal:  Annu Rev Pharmacol Toxicol       Date:  2020-08-31       Impact factor: 13.820

Review 7.  Enhancing oral vaccine potency by targeting intestinal M cells.

Authors:  Ali Azizi; Ashok Kumar; Francisco Diaz-Mitoma; Jiri Mestecky
Journal:  PLoS Pathog       Date:  2010-11-11       Impact factor: 6.823

Review 8.  Application of nanotechnologies for improved immune response against infectious diseases in the developing world.

Authors:  Michael Look; Arunima Bandyopadhyay; Jeremy S Blum; Tarek M Fahmy
Journal:  Adv Drug Deliv Rev       Date:  2009-11-14       Impact factor: 15.470

9.  Radiation-enhanced delivery of systemically administered amphiphilic-CpG oligodeoxynucleotide.

Authors:  Oliver K Appelbe; Kelly D Moynihan; Amy Flor; Nick Rymut; Darrell J Irvine; Stephen J Kron
Journal:  J Control Release       Date:  2017-10-05       Impact factor: 9.776

Review 10.  The twenty-year story of a plant-based vaccine against hepatitis B: stagnation or promising prospects?

Authors:  Tomasz Pniewski
Journal:  Int J Mol Sci       Date:  2013-01-21       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.